<DOC>
	<DOCNO>NCT02539511</DOCNO>
	<brief_summary>Alcohol use disorder remain significant public health problem . The pharmacological facilitation behavioral treatment represent promise strategy addressing disorder drinking . Alcohol use disorder recognize associate various vulnerability complicate course treatment may amenable glutamate modulators . The purpose randomized , double-blind , controlled trial test various glutamate modulators conjunction motivational enhancement therapy ( MET ) alcohol use disorder .</brief_summary>
	<brief_title>Glutamatergic Modulation Disordered Alcohol Use</brief_title>
	<detailed_description>Individuals diagnose alcohol dependence randomize receive single infusion glutamate modulators week 2 engage 5-week course MET . They meet staff twice weekly , except week 2 present clinic three time . Clinic visit include MET session , psychiatric monitoring , assessment , study procedure ( e.g. , medication administration ) .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Active alcohol dependence . In case use drug , alcohol designate primary drug . At least four heavy drinking day past 7 day ( &gt; 4 drink day male , &gt; 3 drink female ) OR minimum weekly use 35 drink male 28 female Physically healthy No adverse reaction study medication 2169 year age Capacity consent comply study procedure , include sufficient proficiency English Seeking reduce stop alcohol use Meets criterion current major depression , bipolar disorder , schizophrenia , psychotic illness , include substance induce psychosis , current substanceinduced mood disorder . Physiological dependence another substance require medical management , opiods benzodiazepine , exclude caffeine , nicotine , cannabis Delirium , Dementia , Amnesia , Cognitive Disorders , Dissociative disorder . Significant dissociative symptom Current suicide risk history suicide attempt within past year Inability safely initiate 24 hour abstinence alcohol ; repeat inability initiate abstinence trial without incur significant withdrawal ; history severe withdrawal phenomenon past 6 month ( e.g. , withdrawalrelated seizure ) ; selfreported inability maintain abstinence 24 hour without substantial distress . Pregnant interested become pregnant study period Any follow cardiac condition : clinically significant leave ventricular hypertrophy , angina , clinically significant arrhythmia , mitral valve prolapse Unstable physical disorder might make participation hazardous endstage AIDS , hypertension ( &gt; 140/90 ) , leukopenia , active hepatitis liver disease elevate transaminase level ( &lt; 23 X upper limit normal consider acceptable clot factor normal ) , renal failure , epilepsy , untreated diabetes Previous history study medication misuse abuse , history adverse reaction/experience prior exposure study medication Recent history significant violence ( past 2 year ) First degree relative psychotic disorder ( bipolar disorder , schizophrenia , schizoaffective disorder , psychosis NOS ) obesity On psychotropic medication whose effect could disrupt participation study BMI &gt; 35</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>